GlaxoSmithKline PLC - West London-based pharmaceutical firm - ViiV Healthcare, the HIV joint venture of GSK, Pfizer Inc and Shionogi & Co Ltd, says interim data from the Carisel study of healthcare teams and people living with HIV shows a positive attitude toward the long-acting HIV-treatment regimen of Vocabria and Rekambys. The study was conducted across Spain, France, Netherlands, Belgium and Germany through surveys and interview during the Covid-19 pandemic. ViiV's Vocabria, or cabotegravir, combined with Rekambys, or rilpivirine, from Johnson & Johnson's Janssen Pharmaceuticals Co is administered every two months under the regimen. ViiV Healthcare says the survey results suggest the regimen is "realistic and achievable in a variety of European healthcare settings".
Current stock price: 1,477.60 pence, up 2.5% on Thursday
Year-to-date change: up 10%
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
